Simethicone
drugOn this page
Also known as ANTIFOAM AANTIFOAM AF
Summary
Simethicone (CHEMBL4297192) is an approved unknown; indicated across 6 conditions including infertility disorder and diarrheal disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- Indications: 6 conditions
- Clinical trials: 33
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297192 |
| Name | Simethicone |
| Type | Unknown |
| Max phase | 4 |
Also known as: ANTIFOAM A, ANTIFOAM AF, Simethicone, SIMETHICONE
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| infertility disorder | 3 | MONDO:0005047 | EFO:0000545 |
| diarrheal disease | 3 | MONDO:0001673 | HP:0002014 |
| dyspepsia | 3 | MONDO:0002268 | EFO:0008533 |
| colorectal neoplasm | 3 | MONDO:0005335 | MONDO:0005575 |
| otitis media | 2 | MONDO:0005441 | EFO:0004992 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 33.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE4 | 12 |
| Not specified | 8 |
| PHASE3 | 4 |
| PHASE2 | 4 |
| PHASE1 | 3 |
| PHASE2/PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06812832 | PHASE4 | RECRUITING | Simethicone as Part of ERAS in Bariatric Surgery Patients |
| NCT00615303 | PHASE4 | COMPLETED | The Effectiveness of Simethicone In Improving Visibility During Colonoscopy |
| NCT01653171 | PHASE4 | COMPLETED | Premedication With Simethicone or Simethicone Plus N-acetylcysteine in Improving Visibility During Upper Endoscopy |
| NCT01711437 | PHASE4 | UNKNOWN | Different Bowel Preparations for Colonoscopy In Children |
| NCT02161367 | PHASE4 | COMPLETED | Effect of Simethicone on Postoperative Ileus in Patients Undergoing Colorectal Surgery |
| NCT02217982 | PHASE4 | TERMINATED | Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation |
| NCT02357303 | PHASE4 | COMPLETED | Simethicone and N-acetylcysteine in Upper Endoscopy - Prospective Double-blinded Randomized Controlled Trial |
| NCT02708238 | PHASE4 | COMPLETED | Efficacy of Matricariae Chamomilla L., Melissa Officinalis L. and Tyndallized Lactobacillus Acidophilus (H122) for Infantile Colics |
| NCT03119168 | PHASE4 | COMPLETED | Effect of Simethicone on Screening Colonoscopy |
| NCT04145856 | PHASE4 | COMPLETED | Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico |
| NCT04709770 | PHASE4 | UNKNOWN | Low-volume vs High-volume Polyethylene Glycol Based Bowel Preparation for Colonoscopy in People Receiving Hemodialysis |
| NCT05570669 | PHASE4 | COMPLETED | Evaluation of Two Different Regimens of Colon Preparations for Advanced Cleaning. |
| NCT02555228 | PHASE2/PHASE3 | COMPLETED | Small Volume Simethicone Before Gastroscopy: Any Benefit? |
| NCT03009604 | PHASE3 | UNKNOWN | Does Simethicone Improve Operative Field in Gynecological Operations |
| NCT03410524 | PHASE3 | COMPLETED | Evaluation of Oral Simethicone With Low Volume Polyethylene Glycol Bowel Preparation During Colonoscopy |
| NCT03429621 | PHASE3 | COMPLETED | Effect of Simethicone on Reducing Bowel Interference During Tubal Resection |
| NCT04802785 | PHASE2/PHASE3 | UNKNOWN | The Impact of Air Travel on Passenger Cognitive Functions |
| NCT05175131 | PHASE3 | COMPLETED | Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders |
| NCT01312038 | PHASE2 | COMPLETED | Effect of Simethicone on Eustachian Tube Dysfunction |
| NCT02846155 | PHASE2 | UNKNOWN | Gastric Preparation of Magnetic-controlled Capsule Endoscopy |
| NCT03467334 | PHASE2 | COMPLETED | Infant Colic Treatment With Probiotics |
| NCT04487834 | PHASE2 | COMPLETED | Effects of Vivatlac Baby on Crying Behavior of Colicky Babies |
| NCT01269671 | PHASE1 | WITHDRAWN | Efficacy of Combination Therapy vs Placebo for Pediatric Functional Abdominal Pain |
| NCT04186936 | PHASE1 | COMPLETED | A Study of Combination Caplet With Loperamide Hydrochloride and Simethicone, and Imodium Express Tablets-lyophilizate Coadministered With Espumisan Capsule in Healthy Volunteers |
| NCT05109390 | PHASE1 | COMPLETED | A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy Adults |
| NCT01209806 | Not specified | COMPLETED | The Effects of Moviprep With Simethicone on Colonic Bubbles |
| NCT01790139 | Not specified | COMPLETED | Oral Iohexol for Fecal/Fluid Tagging for CT Colonography: A Study to Improve Image Quality by Preventing Colonic Bubbles |
| NCT02523911 | Not specified | WITHDRAWN | Efficacy and Tolerability of Suprep With and Without Simethicone for Routine Colonoscopy for Colorectal Cancer Screening |
| NCT02540239 | Not specified | COMPLETED | Premedication Simethione Improves Visibility During Bowel Cleansing for Colonoscopy |
| NCT03166605 | Not specified | UNKNOWN | Ingestion of Simethicone After Capsule Ingestion and Its Impact on Quality of Video Capsule Endoscopy- a Pilot Study |
| NCT03816774 | Not specified | COMPLETED | Effect of Adding Simethicone to Split-dose Polyethylene Glycol for Bowel Preparation in a Screening Colonoscopy Setting |
| NCT04666324 | Not specified | UNKNOWN | Effects of Multilac Baby on Fecal Calprotectin Levels of Colicky Babies |
| NCT05951712 | Not specified | COMPLETED | Pre-medication With N-acetylcysteine and Simethicone to Improve Mucosal Visibility During Gastroduodenoscopy |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).